Search

The basis of any undertaking is known to be an idea. Researchers of Medbiopharm company constantly makes intensive search for new active substances (molecules). The use of the newest biotechnological, chemical synthesis and natural materials processing technologies and also combined processes allows the company  to reach success in this direction.

Expertise

Medbiopharm company does not only use its own prospective ideas but also attracts them from other sources. First of all, they are ideas and results  of researchers of MRRC RAMS, which is safe partner of Medbiopharm company. Many works are the results of long-term cooperation with Russian research institutes and assiduous and many years work of famous scientists. Russian reality does not allow Russian scientists bring their research work to final consumer, people who need in therapy or care for their health. Medbiopharm company helps scientists to launch their production into Russian and foreign markets. Company specialists accumulate great experience which allow to perform full-scale expertise of innovative projects, including their patent clearness and competitive capacity in market. After preparation efficacy and safety proving, the preparation gets start in a life.

Preclinical trials

Medbiopharm company possesses up-to-date  equipment, which allows to perform preparation synthesis or extraction, to plan and carry ut nessesetive experimental studies and trials of new preparations.

After selection of base structure/molecule at the search stage, the stage of clinical trials begins. At this stage a drug substance undergoes laboratory tests and trials in animals to analyze its biological activity, safety and bioavailability. During preclinical trials the efficacy of drug substances is tested in animals at variouse human diseases. Safety tests are basic for active substance. The study of preparation action mechanism allows determining the time of preparation action in organism, frequency and dose of its administration. Preclinical trials also determine ability of transfer to clinical trials.

In average, proving of active substance readiness to clinical trials performance takes several years. But preclinical trials of active substance are hold on even after clinical trials beginning. It is necessary to accumulate data concerning additional action mechanisms, long-term effects and to improve method of selective transportation.